Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency
NCT02806986
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
61
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Immunodeficiency
Interventions
BIOLOGICAL:
IGSC 20%
Sponsor
Grifols Therapeutics LLC